Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Borodovsky

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Pharmacology|October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activityRhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Oncotarget|November 9, 2017
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patientsAvadhut D Joshi, Rachel C Botham, Lisa J Schlein, et al.
Cancer Cell|January 8, 2013
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsJames Kim, Blake T Aftab, Jean Y Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic ResponseBen Sidders, Pei Zhang, Kelly Goodwin, et al.
Journal for Immunotherapy of Cancer|May 16, 2020
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockadeRui Yang, Samah Elsaadi, Kristine Misund, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Journal of Medicinal Chemistry|November 22, 2021
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 MethyltransferaseSharan K Bagal, Clare Gregson, Daniel H O' Donovan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Pharmacology|October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activityRhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Oncotarget|November 9, 2017
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patientsAvadhut D Joshi, Rachel C Botham, Lisa J Schlein, et al.
Cancer Cell|January 8, 2013
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsJames Kim, Blake T Aftab, Jean Y Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic ResponseBen Sidders, Pei Zhang, Kelly Goodwin, et al.
Journal for Immunotherapy of Cancer|May 16, 2020
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockadeRui Yang, Samah Elsaadi, Kristine Misund, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Journal of Medicinal Chemistry|November 22, 2021
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 MethyltransferaseSharan K Bagal, Clare Gregson, Daniel H O' Donovan, et al.
Pageof 2